液体活检在甲状腺癌管理中的转化应用价值

Wijewardene Ayanthi A, Chehade Marthe, Gild Matti L, Clifton-Bligh Roderick J, Bullock Martyn

Department of Endocrinology, Royal North Shore Hospital, Sydney, NSW 2052, Australia.

Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2052, Australia.

Cancers (Basel). 2021 Jul 9;13(14):3443. doi: 10.3390/cancers13143443.

Liquid biopsies are a novel technique to assess for either circulating tumor cells (CTC) or circulating tumor DNA (ctDNA and microRNA (miRNA)) in peripheral blood samples of cancer patients. The diagnostic role of liquid biopsy in oncology has expanded in recent years, particularly in lung, colorectal and breast cancer. In thyroid cancer, the role of liquid biopsy in either diagnosis or prognosis is beginning to translate from the lab to the clinic. In this review, we describe the evolution of liquid biopsies in detecting CTC, ctDNA and miRNA in thyroid cancer patients, together with its limitations and future directions in clinical practice.

液体活检是一种用于评估癌症患者外周血样本中循环肿瘤细胞（CTC）或循环肿瘤DNA（ctDNA）及微小RNA（miRNA）的新技术。近年来，液体活检在肿瘤学中的诊断作用不断扩大，尤其是在肺癌、结直肠癌和乳腺癌方面。在甲状腺癌中，液体活检在诊断或预后方面的作用正开始从实验室转化到临床。在本综述中，我们描述了液体活检在检测甲状腺癌患者的CTC、ctDNA和miRNA方面的发展历程，以及其在临床实践中的局限性和未来方向。